2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 3 min
0,63 USD/osake
Viimeisin osinko
2,56%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 16.4. | ||
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 15.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 16.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17.4.The most important in the report now * Q1 2026 EPS was $1,15, slightly above expectation * Revenue $11,16 bn. * Medical Devices grew 8,5 % * Libre is still growing, but slightly slower than the market had hoped * Guidance was lowered due to the Exact Sciences acquisition What the market reacts negatively to * 2026 EPS guidance down from: 5,55–5,80 → 5,38–5,58 * The Nutrition segment is still weak * The Diabetes segment is growing, but not quite as strong as expected Where Abbott is still strong Abbott is still extremely strong because they own several structural growth engines: * Abbott Laboratories FreeStyle Libre * structural heart * diagnostics * nutrition globalt * emerging markets pharma This provides very high robustness. Where it stands in my quality ranking now Over Abbott: * Stryker Corporation * Zoetis Inc. * Danaher Corporation On par with: * AbbVie Inc. * Coloplast A/S Intrinsic value right now My realistic range is: 110–118 USD The stock is currently trading around 95 USD, so there is still upside of approximately 15–20 %, but the market wants to see proof that Libre is accelerating again.
·20.11.2025Abbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
·12.7.2025Fantastically diversified company, one of the best in stock history in the US. Check out Jeremy Siegel's Stocks for The Long Run where the company is mentioned.
14.3.2022 · Muokattu14.3.2022 · Muokattuthis company has not pulled out from Russia Over 300 Companies Have Withdrawn from Russia—But Some Remain | Yale School of Management https://som.yale.edu/story/2022/over-300-companies-have-withdrawn-russia-some-remain
31.1.2022 · Muokattu31.1.2022 · MuokattuGood news 10 Dec 2021: Abbott Increases Quarterly Dividend for 50th Consecutive Year - Dividend increased by 4.4%; follows a 25% increase in 2021 - Board of directors also has authorized a new share repurchase program - Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend, marking the company's 50th consecutive year of dividend growth. Abbott's quarterly common dividend has been increased to 47 cents per share, a 4.4% increase that follows a 25% increase to the company's quarterly dividend in 2021. It will be the 392nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2022, to shareholders of record at the close of business on Jan. 14, 2022.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 3 min
0,63 USD/osake
Viimeisin osinko
2,56%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17.4.The most important in the report now * Q1 2026 EPS was $1,15, slightly above expectation * Revenue $11,16 bn. * Medical Devices grew 8,5 % * Libre is still growing, but slightly slower than the market had hoped * Guidance was lowered due to the Exact Sciences acquisition What the market reacts negatively to * 2026 EPS guidance down from: 5,55–5,80 → 5,38–5,58 * The Nutrition segment is still weak * The Diabetes segment is growing, but not quite as strong as expected Where Abbott is still strong Abbott is still extremely strong because they own several structural growth engines: * Abbott Laboratories FreeStyle Libre * structural heart * diagnostics * nutrition globalt * emerging markets pharma This provides very high robustness. Where it stands in my quality ranking now Over Abbott: * Stryker Corporation * Zoetis Inc. * Danaher Corporation On par with: * AbbVie Inc. * Coloplast A/S Intrinsic value right now My realistic range is: 110–118 USD The stock is currently trading around 95 USD, so there is still upside of approximately 15–20 %, but the market wants to see proof that Libre is accelerating again.
- ·20.11.2025Abbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
- ·12.7.2025Fantastically diversified company, one of the best in stock history in the US. Check out Jeremy Siegel's Stocks for The Long Run where the company is mentioned.
- 14.3.2022 · Muokattu14.3.2022 · Muokattuthis company has not pulled out from Russia Over 300 Companies Have Withdrawn from Russia—But Some Remain | Yale School of Management https://som.yale.edu/story/2022/over-300-companies-have-withdrawn-russia-some-remain
- 31.1.2022 · Muokattu31.1.2022 · MuokattuGood news 10 Dec 2021: Abbott Increases Quarterly Dividend for 50th Consecutive Year - Dividend increased by 4.4%; follows a 25% increase in 2021 - Board of directors also has authorized a new share repurchase program - Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend, marking the company's 50th consecutive year of dividend growth. Abbott's quarterly common dividend has been increased to 47 cents per share, a 4.4% increase that follows a 25% increase to the company's quarterly dividend in 2021. It will be the 392nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2022, to shareholders of record at the close of business on Jan. 14, 2022.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 16.4. | ||
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 15.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 16.4.2025 |
2026 Q1 -tulosraportti
13 päivää sitten
‧1 t 3 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 16.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 16.4. | ||
2025 Q4 -tulosraportti 22.1. | ||
2025 Q3 -tulosraportti 15.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 16.4.2025 |
0,63 USD/osake
Viimeisin osinko
2,56%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17.4.The most important in the report now * Q1 2026 EPS was $1,15, slightly above expectation * Revenue $11,16 bn. * Medical Devices grew 8,5 % * Libre is still growing, but slightly slower than the market had hoped * Guidance was lowered due to the Exact Sciences acquisition What the market reacts negatively to * 2026 EPS guidance down from: 5,55–5,80 → 5,38–5,58 * The Nutrition segment is still weak * The Diabetes segment is growing, but not quite as strong as expected Where Abbott is still strong Abbott is still extremely strong because they own several structural growth engines: * Abbott Laboratories FreeStyle Libre * structural heart * diagnostics * nutrition globalt * emerging markets pharma This provides very high robustness. Where it stands in my quality ranking now Over Abbott: * Stryker Corporation * Zoetis Inc. * Danaher Corporation On par with: * AbbVie Inc. * Coloplast A/S Intrinsic value right now My realistic range is: 110–118 USD The stock is currently trading around 95 USD, so there is still upside of approximately 15–20 %, but the market wants to see proof that Libre is accelerating again.
- ·20.11.2025Abbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
- ·12.7.2025Fantastically diversified company, one of the best in stock history in the US. Check out Jeremy Siegel's Stocks for The Long Run where the company is mentioned.
- 14.3.2022 · Muokattu14.3.2022 · Muokattuthis company has not pulled out from Russia Over 300 Companies Have Withdrawn from Russia—But Some Remain | Yale School of Management https://som.yale.edu/story/2022/over-300-companies-have-withdrawn-russia-some-remain
- 31.1.2022 · Muokattu31.1.2022 · MuokattuGood news 10 Dec 2021: Abbott Increases Quarterly Dividend for 50th Consecutive Year - Dividend increased by 4.4%; follows a 25% increase in 2021 - Board of directors also has authorized a new share repurchase program - Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend, marking the company's 50th consecutive year of dividend growth. Abbott's quarterly common dividend has been increased to 47 cents per share, a 4.4% increase that follows a 25% increase to the company's quarterly dividend in 2021. It will be the 392nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2022, to shareholders of record at the close of business on Jan. 14, 2022.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt